U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H25N5O5
Molecular Weight 451.4751
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXAZOSIN

SMILES

COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4

InChI

InChIKey=RUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)

HIDE SMILES / InChI

Molecular Formula C23H25N5O5
Molecular Weight 451.4751
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

Originator

Curator's Comment: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARDURA

Approved Use

INDICATIONS AND USAGE A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors.

Launch Date

1990
Primary
CARDURA

Approved Use

INDICATIONS AND USAGE A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.7 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.6 ng/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14.3 ng/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
151.7 ng/mL
16 mg 1 times / day steady-state, oral
dose: 16 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
42.3 ng/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
65.5 ng/mL
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
162 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
268 ng × h/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.9 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15 h
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 h
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.6 h
16 mg 1 times / day steady-state, oral
dose: 16 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.8 h
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.3 h
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 19 years
n = 1
Health Status: healthy
Age Group: 19 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Sinus tachycardia...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia (1 patient)
Sources:
16 mg single, oral (max)
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
unhealthy, adult
n = 665
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: unknown
Population Size: 665
Sources:
DLT: Postural edema...
Dose limiting toxicities:
Postural edema (2.7%)
Sources:
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
healthy, adult
n = 35
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 35
Sources:
Disc. AE: Orthostatic dizziness...
AEs leading to
discontinuation/dose reduction:
Orthostatic dizziness (1 patient)
Sources:
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Disc. AE: Fatigue, Urinary incontinence...
Other AEs: Rhinitis...
AEs leading to
discontinuation/dose reduction:
Fatigue (3 patients)
Urinary incontinence (2 patients)
Other AEs:
Rhinitis (1 patient)
Sources:
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Other AEs: Nausea, Constipation...
Other AEs:
Nausea (below serious, 2 patients)
Constipation (below serious, 1 patient)
Allergy (below serious, 1 patient)
Dizziness (below serious, 1 patient)
Numbness (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinus tachycardia 1 patient
Disc. AE
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 19 years
n = 1
Health Status: healthy
Age Group: 19 years
Sex: F
Population Size: 1
Sources:
Postural edema 2.7%
DLT
16 mg single, oral (max)
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
unhealthy, adult
n = 665
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: unknown
Population Size: 665
Sources:
Orthostatic dizziness 1 patient
Disc. AE
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
healthy, adult
n = 35
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 35
Sources:
Rhinitis 1 patient
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Urinary incontinence 2 patients
Disc. AE
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Fatigue 3 patients
Disc. AE
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Allergy below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Constipation below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Dizziness below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Numbness below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Nausea below serious, 2 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
2001
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats.
2001
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction.
2001
Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosin.
2001 Apr
Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1.
2001 Aug 1
Tamsulosin: current clinical experience.
2001 Dec
Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects.
2001 Jan
pH-mediated field-amplified sample stacking of pharmaceutical cations in high-ionic strength samples.
2001 Jan
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
2001 Jan
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is Cadura safe?
2001 Jul
Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
2001 Jul
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.
2001 Jul
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
2001 Jul 1
Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.
2001 Jul-Aug
US FDA weighs options for warning on antihypertensive drug.
2001 Jun 2
[Long-term therapy of benign prostatic hyperplasia. Our experience].
2001 Mar
The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers.
2001 Mar
The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy.
2001 Mar
Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.
2001 May 17
[Doksazozin "Cardura" in acute urinary retention caused by benign prostatic hyperplasia].
2001 May-Jun
Effects of antihypertensive agents on blood pressure during exercise.
2001 Nov
Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure.
2001 Oct
The choice of antihypertensive drugs in patients with erectile dysfunction.
2002
Effect of doxazosin on rat urinary bladder function after partial outlet obstruction.
2002
Acute effects of serotonin on rat bladder contractility.
2002
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
2002 Aug
Medical therapy for benign prostatic hyperplasia progression.
2002 Aug
Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia.
2002 Aug
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
2002 Aug 6
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
2002 Feb
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
2002 Jan 15
Doxazosin, an inferior antihypertensive agent?
2002 Jun
Doxazosin and congestive heart failure.
2002 May-Jun
Patents

Patents

Sample Use Guides

Usual Adult Dose for Hypertension Initial dose: 1 mg orally once a day. Maintenance dose: 1 to 16 mg orally once a day. Usual Adult Dose for Benign Prostatic Hyperplasia Initial dose: Immediate-release: 1 mg orally once a day. Extended-release: 4 mg orally once a day with breakfast Maintenance dose: Immediate-release: 1 to 8 mg orally once a day. Extended-release: 4 to 8 mg orally once a day with breakfast. Depending on the patient's symptomatic response and tolerability, the dose may be increased to 8 mg (the maximum recommended dose). The recommended titration interval is 3 to 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Ring segments of splanchnic, peripheral, coronary, pulmonary and uterine conduit arteries obtained during surgery were studied in tissue baths. Resistance arteries dissected from various sites were studied in a myograph. Both conduit and resistance vessels contracted in response to the alpha 1-agonist phenylephrine (10(-7) to 10(-4) mol/l), an effect that was antagonized by the alpha 1-antagonist doxazosin (10(-8) to 10(-6) mol/l).
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:39:35 GMT 2023
Edited
by admin
on Sat Dec 16 17:39:35 GMT 2023
Record UNII
NW1291F1W8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXAZOSIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
DOXAZOSIN [MI]
Common Name English
C02CA04
Code English
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE
Systematic Name English
(±)-DOXAZOSIN
Common Name English
(4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHANONE
Systematic Name English
doxazosin [INN]
Common Name English
PIPERAZINE, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)CARBONYL)-
Systematic Name English
DOXAZOSIN [VANDF]
Common Name English
METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-
Systematic Name English
Doxazosin [WHO-DD]
Common Name English
UK-33274
Code English
CARDURA XL
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175553
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
NDF-RT N0000000099
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
NCI_THESAURUS C29713
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
LIVERTOX NBK548718
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
WHO-VATC QC02CA04
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
WHO-ATC C02CA04
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
NCI_THESAURUS C29707
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
Code System Code Type Description
WIKIPEDIA
DOXAZOSIN
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
DAILYMED
NW1291F1W8
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
RXCUI
49276
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY RxNorm
CAS
74191-85-8
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
PUBCHEM
3157
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
LACTMED
Doxazosin
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
SMS_ID
100000080772
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
INN
5143
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
MERCK INDEX
m4752
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL707
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
IUPHAR
7170
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
CHEBI
4708
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
DRUG CENTRAL
954
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
NCI_THESAURUS
C61737
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID7022964
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
MESH
D017292
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
FDA UNII
NW1291F1W8
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
CAS
137888-77-8
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
SUPERSEDED
EVMPD
SUB06384MIG
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
DRUG BANK
DB00590
Created by admin on Sat Dec 16 17:39:36 GMT 2023 , Edited by admin on Sat Dec 16 17:39:36 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
known active and inactive metabolites of doxazosin were detected
METABOLITE -> PARENT
known active and inactive metabolites of doxazosin were detected
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
MINOR
FECAL; URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
FECAL; URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC